Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · Krane Shares

KraneShares MSCI All China Health Care Index ETF (KURE)

Ticker KURE · Index fund · Since 2018-01-31 · · Holdings as of Jun 30, 2026

Expense ratio
0.65%$65/yr per $10k
5-yr return
−11.8%annualized
1-yr return
+24.8%as of Dec 2025
Net assets
$71.2Mall share classes
Holdings
63

Bottom line

Is KURE a good fund? The bottom line

KURE is an index health care sector ETF from Krane Shares.

It charges 0.65% — about $65 a year on every $10,000 invested, cheaper than 74% of health care sector funds we track.

It returned +24.8% over one year, −11.8% a year over five years (as of Dec 31, 2025, per its prospectus).

With $71.2 million in net assets and 63 holdings, its largest position is BeOne Medicines AG (8.8%) and the top 10 make up 54.1% of the portfolio.

What to watch

  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 54.1% of assets

Updated Nov 19, 2026

What KURE invests in

The KraneShares MSCI All China Health Care Index ETF (the Fund) seeks to provide investment results that, before fees and expenses, track the price and yield performance of a specific foreign equity securities index. The Funds current index is the MSCI China All Shares Health Care 10/40 Index (the Underlying Index).

Under normal circumstances, the Fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its Underlying Index or in instruments that have economic characteristics similar to those in the Underlying Index. The Underlying Index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint (as defined below), which is designed to measure the equity market performance of Chinese companies in the healthcare sector, as classified by the Global Industry Classification Standard. The securities eligible for inclusion in the Underlying Index include all types of publicly issued shares of Chinese issuers, such as A-Shares, B-Shares, H-Shares, P-Chips and Red Chips, which are described below. The issuers included in the Underlying Index may include mid-cap and large-cap companies. To determine the investable…

From the fund's prospectus (filed Jul 31, 2026).

KURE performance

Fund calendar-year total returns, 2019–2025 2019: +34.0%; 2020: +67.3%; 2021: −15.9%; 2022: −25.4%; 2023: −17.3%; 2024: −17.4%; 2025: +24.8% +34.0% 2019 +67.3% 2020 −15.9% 2021 −25.4% 2022 −17.3% 2023 −17.4% 2024 +24.8% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
KURE+24.8%−11.8%—
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full KURE performance history →

What KURE costs

On a $10,000 investment, KURE's 0.65% expense ratio costs about $65 a year. The prospectus estimates $951 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full KURE fee table →

KURE top 10 holdings

#Holding% of fund
1BeOne Medicines AG8.84%
2Innovent Biologics, Inc.8.80%
3Wuxi Biologics (cayman) Inc.7.51%
4WuXi AppTec Co., Ltd.5.79%
5Jiangsu Hengrui Pharmaceuticals Co.,Ltd4.59%
6Shenzhen Mindray Bio-Medical Electronics Co Ltd4.27%
7Akeso Inc3.72%
8Cspc Pharmaceutical Group Limited3.68%
9Invesco Government & Agency Portfolio3.55%
10Sino Biopharmaceutical Limited3.39%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 54.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to KURE

More funds like KURE →

KURE FAQ

What is the expense ratio of KURE?
KURE's expense ratio is 0.65%, which works out to about $65 a year for every $10,000 invested. The prospectus estimates total costs of $951 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is KURE a good investment?
It depends on your goals, but the data points to: 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 54.1% of assets. This is general information, not personalized advice.
What does KURE hold?
KURE's largest holdings are BeOne Medicines AG (8.8%), Innovent Biologics, Inc. (8.8%), Wuxi Biologics (cayman) Inc. (7.5%), WuXi AppTec Co., Ltd. (5.8%), Jiangsu Hengrui Pharmaceuticals Co.,Ltd (4.6%). It holds 63 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is KURE's 5-year return?
KURE returned −11.8% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Who manages KURE?
KURE is offered by Krane Shares through Krane Shares Trust.